Back to search

Article

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small cell lung cancer brain metastases: A comparative study

2025-10-15

Abstract excerpt

<title>Abstract</title> <p> Background Brain metastases (BMs) are common in patients with non-small cell lung cancer (NSCLC) and remain a major therapeutic challenge. While immune checkpoint inhibitors (ICIs) have improved systemic outcomes, their Intracranial efficacy and prognostic determinants in patients with BMs, particularly in comparison with chemotherapy, remain insufficiently characterized. Methods We c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eb9778e3-0d40-5ee6-a8a9-6ae9df9bfe1d
DOI
10.21203/rs.3.rs-7676603/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical outcomes and predictive factors of immunotherapy efficacy in non-small cell lung cancer brain metastases: A comparative studyDOI 10.21203/rs.3.rs-7676603/v1
Brain Radiotherapy Combined with Immune Checkpoint Inhibitors and Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer with Brain Metastases: A Retrospective StudySemantic proximity
The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain MetastasesSemantic proximity
Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.Semantic proximity
Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.Semantic proximity
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?Semantic proximity
Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity
Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity
Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of LiteratureSemantic proximity
Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.Semantic proximity
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity
Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastasesSemantic proximity
Select a neighboring publication to make it the new centre.